key: cord-0895437-m2rbn24k
authors: Criado, Paulo R.; Criado, Roberta F. J.; Pincelli, Thais P.; Yoshimoto, Thais A.; Naufal, Gabriela G. A.; Abdalla, Beatrice M. Z.
title: Chronic spontaneous urticaria exacerbation in a patient with COVID‐19: rapid and excellent response to omalizumab
date: 2020-08-17
journal: Int J Dermatol
DOI: 10.1111/ijd.15134
sha: 0d9e85d297887f695849c51b1e20dcb234803338
doc_id: 895437
cord_uid: m2rbn24k

nan

19. Shortly after symptom onset, she noticed exacerbation of urticaria and angioedema (UAS7 = 42 and UCT = 6). Peripheral O2 saturation was 95%, and thorax computed tomography (CT) demonstrated mild thickened lobular septum (Fig. 1a) . She received a 7-day course of amoxicillin-clavulanate, and followup CT showed bilateral lung involvement with ground-glass opacities (Fig. 1b) .

During COVID-19, her CSU was refractory to deflazacort 30 mg/day, bilastine 80 mg/day, and ketotifen 2 mg/day ( Fig. 1c-e) , when anosmia and ageusia were still present.

Omalizumab 300 mg subcutaneously was initiated, with complete resolution of urticaria and itching after 72 hours. Improvement of all COVID-19 symptoms was also noted. She remained on bilastine 80 mg/day and omalizumab 300 mg every 4 weeks, with a total of three injections, without new flares. (Fig. 2 ). 

Association between urticaria and virus infections: a systematic review

Urticaria associated with Norovirus infection: report of two cases

Early Insights into immune responses during COVID-19

Response of FceRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria

Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy